I
nflammatory processes play an important role in the pathogenesis of atherosclerosis. Recruitment of mononuclear leukocytes and the migration, growth, and activation of multiple cell types within atherosclerotic lesions are critical features of the chronic inflammatory and fibroproliferative response central to atherosclerosis. The atherosclerotic vascular wall itself contains elevated levels of acute-phase proteins and proinflammatory cytokines, resulting in localized inflammatory effects eventually responsible for intimal thickening and plaque disruption. Predominant cytokines (that are also elevated in plasma) include tumor necrosis factor ␣ (TNF-␣) and interleukin 6 (IL-6). 1 Sphingolipids and their metabolic products are known to have second messenger functions in a variety of cellular signaling pathways. Ceramide is found in endothelial cells, smooth muscle cells, monocytes, macrophages, neutrophils, and platelets. Endogenous ceramide is generated from sphingomyelin by the action of sphingomyelinase (SMase) or by de novo synthesis coordinated through the enzyme ceramide synthase. 2 Molecules promoting atherosclerosis such as oxidized low-density lipoprotein (oxLDL), inflammatory cytokines (TNF-␣ and IL-1␤), or growth factors stimulate sphingomyelin hydrolysis and ceramide generation. 3 Also, the ceramide content of lesional LDL is markedly increased compared with plasma LDL, 4 and ceramide has been found to accumulate in atherosclerotic lesions. 5 Ceramide can stimulate IL-6 gene expression 6 and, subsequently, C-reactive protein, which is likely to have direct proinflammatory effects and to contribute to the atherosclerotic process. 7 Treatment of human vascular endothelial cells with cellpermeable synthetic ceramide or bacterial SMase elicited E-selectin-dependent adhesion of quiescent leukocytes to endothelial cells, an important onset event in atherogenesis. 8 Development of atherosclerosis is believed to involve prolif-eration of smooth muscle cells (SMCs). Activation of the sphingomyelin-ceramide pathway has been suggested to play a pivotal role in the oxLDL-induced SMC proliferation. 9 Thus, ceramide seems to be implicated in several ways in the atherogenic process. 8, 10 Conversely, there is evidence in the literature that ceramide can have positive effects on vascular NO production. NO generated by endothelial NO synthase (eNOS) conveys vasoprotection and antiatherosclerotic effects through several mechanisms. 11 For example, ceramide has been shown to activate eNOS in bovine aortic endothelial cells independently of calcium and to enhance NO production. 12 In rat aortic rings, ceramide induced vasorelaxation that was partially NO mediated. 13 Also, short-term exposure of endothelial cells to TNF-␣ 14 or binding of high-density lipoprotein to scavenger receptors 15 has been shown to activate eNOS in endothelial cells; intracellular ceramide has been identified as the second messenger for both processes. On the other hand, ceramide has been shown to promote generation of reactive oxygen species (ROS) in bovine coronary arteries, 16 and ROS can rapidly destroy bioactive NO.
Therefore, the present study was designed to investigate long-term effects of ceramide on the biochemical determinants of bioactive NO, namely eNOS expression, eNOS activity, and the concomitant ROS generation.
Methods

Cell Culture
Human umbilical vein endothelial cells (HUVECs) and HUVECderived EA.hy 926 endothelial cells were cultured as previously described. 17 HUVECs of passages 3 to 5 were used.
Analysis of eNOS mRNA and Protein Expression
Confluent cells were incubated with ceramide for the times indicated in the Results section. Kinase and phosphatase inhibitors were given 1 hour before ceramide. The expression of eNOS mRNA was analyzed by RNase protection assay. 17 Protein expression of eNOS was determined by Western blot using a polyclonal rabbit anti-eNOS antibody. The detailed procedure has been described previously. 17 
Analysis of eNOS Promoter Activity
Promoter activity was analyzed by reporter gene assay using the plasmid pGl 3 -eNOS-Hu-1600 transiently transfected into EA.hy 926 cells. The plasmid contains a 1.6-kb human eNOS promoter fragment (Ϫ1600 to ϩ23) cloned before the luciferase gene of pGl 3 4 ) , and the conditioned media from the EA.hy 926 cells were transferred to the RFL-6 cells, as previously described. 17 The cGMP content of the RFL-6 samples was determined by radioimmunoassay. 17 To determine the total synthesis of NO, nitrite and nitrate were measured in the supernatant of EA.hy 926 cells after treatment with C6-ceramide for 9 hours. After reduction of nitrate with nitrate reductase, total nitrite was determined by chemiluminescence using a NOA 280 Nitric Oxide Analyzer (Sievers). 18 Total protein content of the cells was determined (Bradford), and nitrite levels were normalized for protein. 18 
Measurement of Intracellular Reactive Oxygen Species
The determination of intracellular oxidant formation was based on the oxidation of 5-(and-6)-chloromethyl-2Ј,7Ј-dichlorodihydrofluorescein diacetate (CM-H 2 DCFDA) to yield an intracellular trapped fluorescent compound and the fluorescence measured in a FluoroCount Reader (Packard Bioscience). Confluent EA.hy 926 cells in 96-well plates were treated for 9 hours with the indicated concentrations of C6-ceramide, then washed with Hanks' buffered saline solution (HBBS, Invitrogen) and incubated for 30 minutes with 10 mol/L of CM-H 2 DCFDA in HBBS. Thereafter, cells were washed twice with HBBS and incubated for an additional 2 hours before measuring the fluorescence at excitation and emission wavelengths of 488 nm and 530 nm, respectively. 19 
Statistics
Statistical differences between mean values were determined by ANOVA followed by Fisher's protected least-significant difference test for comparison of different means.
Results
C6-Ceramide Incubation Reduced Bioactive NO
When HUVEC-derived EA.hy 926 endothelial cells were treated with C6-ceramide for 9 hours, bioactive NO was decreased in a concentration-dependent manner ( Figure 1 ).
C6-Ceramide Upregulated eNOS mRNA Expression in Human Vascular Endothelial Cells in a Concentration-and Time-Dependent Manner
To test whether the reduced NO production in response to ceramide correlated with a reduced eNOS expression, we analyzed eNOS mRNA expression with RNase protection assay. Surprisingly, C6-ceramide enhanced eNOS mRNA expression in a concentration-and time-dependent manner in EA.hy 926 cells (Figure 2A through 2C) . Also, in HUVECs treated with 10 mol/L C6-ceramide for 9 hours, a significant upregulation of eNOS mRNA was observed ( Figure 2D ). In human endothelial cells, C6-ceramide did not induce the mRNA expression of inducible-type NOS (3 experiments, data not shown). 
C6-Ceramide Enhanced eNOS Promoter Activity but Did Not Change the Stability of the eNOS mRNA
In EA.hy 926 cells transfected with pGl 3 -eNOS-Hu-1600, the eNOS promoter fragment showed a significant basal activity (control) compared with the vector pGl 3 Human EA.hy 926 endothelial cells were incubated for 9 hours with 10 mol/L C6-ceramide, alone or in combination with PP2A inhibitors (okadaic acid or calyculin A, both 10 nmol/L), a PP1 inhibitor (tautomycin, 100 nmol/L), PKC inhibitors (GF 109203X or Gö 6983, both 1 mol/L), or the inhibitor of the MAPK kinase, MEK-1 (PD 98059, 10 mol/L). As shown in Figure 5 , none of the inhibitors affected the eNOS expression when used alone. The PP2A inhibitors, but not the inhibitors of PP1, PKC, or MEK-1, reduced the upregulation of eNOS expression by C6-ceramide.
Effect of Ceramide on ROS Production and eNOS Uncoupling
Upregulation of eNOS (Figures 2 and 3 ) was associated with a decreased production of bioactive NO (Figure 1) . However, the total synthesis of NO (measured as nitrite and nitrate) increased in parallel with eNOS expression after exposure of EA.hy 926 cells to ceramide for 9 hours: 119.5Ϯ5.8% of control after 3 mol/L C6-ceramide and 142.4Ϯ12.9% of control after 10 mol/L C6-ceramide (meanϮSEM, PϽ0.05, 4 experiments). This suggests that NO synthesis is indeed increased but there is an accelerated oxidation of NO after ceramide.
Because ROS can rapidly oxidize and inactivate NO, we measured ROS in EA.hy 926 cells after a 9-hour incubation with C6-ceramide. As shown in Figure 6 , ROS generation was increased by C6-ceramide. ROS production can result from several enzymes, including the NADPH oxidase activity of uncoupled eNOS itself. 24 Indeed, ceramide-induced ROS 
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production was partially prevented by a NOS inhibitor, N G -nitro-L-arginine methyl ester (L-NAME, Figure 6 ). A major cause of eNOS uncoupling in vivo can be a BH 4 deficiency. 25 Therefore, we supplemented ceramide-treated cells (and controls) with BH 4 in the incubation media. The ceramide-induced reduction in bioactive NO was normalized by BH 4 (Figure 7 ).
C6-Ceramide-Induced eNOS Upregulation Was Not Mediated by ROS
ROS, especially hydrogen peroxide (H 2 O 2 ), has been shown to upregulate eNOS expression in endothelial cells. 26, 27 Thus, ceramide-induced eNOS expression could have been the consequence of an increased H 2 O 2 production. However, the eNOS mRNA expression induced by ceramide was not prevented by catalase (1000 U/mL) or by the antioxidant N-acetylcysteine (5 mmol/L, 3 experiments each, data not shown). Moreover, H 2 O 2 -induced eNOS upregulation has been reported to be mediated by Ca 2ϩ /calmodulin-dependent kinase II and janus kinase 2. 27 Inhibitors of these kinases (KN-93 and AG 490, both 10 mol/L) did not affect the ceramide-induced eNOS mRNA expression in EA.hy 926 cells (3 experiments each, data not shown).
Discussion
Ceramide is a second messenger molecule that seems to play an important role in the process of atherogenesis. 3, 10, 28 However, potential antiatherosclerotic effects also have been reported for this signaling molecule. Particularly, the reports demonstrating a stimulation of endothelial NO synthesis would suggest antiatherosclerotic properties.
In precontracted rat aortic rings, bacterial SMase and cell-permeable synthetic ceramide caused vasorelaxation in a concentration-dependent manner; removal of the endothelium reduced these relaxations. 13 Ceramide has been shown to produce translocation and activation of eNOS in bovine aorta endothelial cells through a Ca 2ϩ -independent mechanism. 12 Moreover, short-term TNF-␣ exposure 14 or binding of highdensity lipoprotein to scavenger receptors 15 leads to a ceramide-dependent activation of eNOS in endothelial cells. On the other hand, in isolated bovine coronary arteries, ceramide has been shown to increase O 2 ·Ϫ generation, thereby producing endothelial dysfunction and reducing NOmediated vasodilation. 16 Against this background of NO-increasing and NOreducing effects of ceramide reported in different animal models, we decided to determine the release of biologically active NO (measured by the stimulation of soluble guanylyl cyclase) from human endothelial cells. C6-ceramide clearly reduced bioactive NO (Figure 1) . At the same time, the producing enzyme, eNOS, was upregulated at the mRNA and protein levels (Figures 2 and 3 ). This was a transcriptional effect on the eNOS promoter that involved PP2A (Figures 4  and 5) , one of the known target enzymes of ceramide. 22, 23 The discrepancy between increased expression and decreased activity of eNOS is resolved in Figure 6 , which demonstrates that ceramide also stimulated ROS production in human endothelial cells. ROS can rapidly oxidize NO, thereby reducing its bioactivity. Thus, ceramide produced oxidative stress in endothelial cells, a finding that is in accordance with a recent study in small bovine coronary arteries. 16 The enzyme systems in EA.hy 926 cells responsible for ROS production in response to ceramide remain to be determined. Potential sources of O 2 ·Ϫ /ROS include NAD(P)H oxidase, xanthine oxidase, and the mitochondrial respiratory chain. In human aortic smooth muscle cells, ceramide activates NAD(P)H oxidase and increases O 2 ·Ϫ production. 29 In HUVECs, ceramide has also been shown to interact with the mitochondrial electron transport chain, leading to the generation of ROS. 30 An increased oxidation of BH 4 by peroxynitrite/O 2 ·Ϫ may cause BH 4 deficiency, which favors NADPH oxidase activity of eNOS leading to the formation of ROS (O 2 ·Ϫ and H 2 O 2 ) in lieu of NO. 24 This phenomenon is often referred to as eNOS uncoupling. 24 Interestingly, in EA.hy 926 cells, the ceramideinduced reduction in bioactive NO could be largely normalized when the cells were treated with BH 4 (Figure 7 ). This suggests that ceramide led to an uncoupling of eNOS and that eNOS itself contributed to ROS production ( Figure 6 ). This assumption is substantiated by the finding that the NOS inhibitor L-NAME partially prevented endothelial ROS generation ( Figure 6 ). NO production by eNOS correlates closely with the intracellular concentration of BH 4 , and supplementation with BH 4 has been shown to correct eNOS dysfunction in several types of pathophysiology, such as hypertension, experimental diabetes, and hypercholesterolemia, and in smokers. 24 However, BH 4 supplementation does not affect ROS generation from sources other than eNOS, which may explain why NO bioavailability was not increased parallel to eNOS expression, even when eNOS uncoupling was corrected by BH 4 supplementation (Figures 2 and 7) .
Several pathophysiological conditions of oxidative stress, such as angiotensin II-induced hypertension, 31 streptozotocininduced diabetes, 32 or nitroglycerin tolerance, 33 have been shown to go along with an upregulation of eNOS expression, which may be considered an unsuccessful compensatory mechanism. The same seems to be true for ceramide signaling. Future research may determine whether ceramide signaling is involved in some of those pathophysiological situations.
In conclusion, we identified the lipid second-messenger ceramide as a regulator of eNOS expression in human endothelial cells. Incubation of human endothelial cells with exogenous cell-permeable C6-or C8-ceramide or with bacterial SMase (which increases intracellular ceramide contents by hydrolysis of sphingomyelin) increased eNOS transcription. However, despite the upregulation of eNOS expression, ceramide produces oxidative stress in endothelial cells and reduces bioactive NO. The decreased NO bioavailability is likely to favor a proatherogenic role of ceramide.
